Global Market Outlook: Rising Obesity and Supplement Demand Global obesity rates have more than doubled since 1990 , with approximately 890 million adults living with obesity worldwide in 2022 ( WHO - Obesity and Overweight )
Moore, Edie, Abram
GLP-1 agonists like liraglutide (Victoza), lixisenatide (Adlyxin), dulaglutide (Trulicity), and semaglutide (Ozempic, Rybelsus) are commonly prescribed and continue to demonstrate benefits beyond just controlling blood sugar, including improvements in heart and metabolic health for some drugs
These studies uniformly showed that Liraglutide significantly reduced body weight when used as an adjunct therapy with diet and exercise
At our Los Angeles clinic, patients consistently report high satisfaction rates, praising Dr
Dehydration interferes with the body's ability to break down fat and turn it into fuel